Related Experiment Video
Updated: Jul 3, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin
Rachael O'Connor1, Simon D Baines, Jane Freeman
1Department of Microbiology, Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.
Objectives:
Clostridium difficile infection is a nosocomial disease of increasing importance. First-line treatment is limited to metronidazole or vancomycin. Oritavancin is a lipoglycopeptide with activity against Gram-positive bacteria, including drug-resistant pathogens. MICs of oritavancin, metronidazole and vancomycin for genotypically distinct C. difficile strains, including epidemic C. difficile PCR ribotypes 001 and 027, were determined by agar incorporation and broth macrodilution methods. In agar incorporation methods, the impact of supplements on oritavancin MICs was tested to address oritavancin binding to surfaces.
Methods:
Thirty-three genotypically distinct C. difficile strains were identified by PCR ribotyping. Wilkins Chalgren agar incorporation plates containing oritavancin, metronidazole and vancomycin were prepared with and without 0.002% polysorbate-80 (P80) and lysed horse blood (2%). Broth macrodilution MICs of oritavancin, metronidazole and vancomycin were determined in Brucella broth. Inoculated agar incorporation plates and broth macrodilution tubes were cultured anaerobically at 37 degrees C for 48 h.
Results:
Broth macrodilution MICs were lower than agar incorporation MICs for oritavancin, but not for metronidazole and vancomycin. Oritavancin broth macrodilution MIC(90)s were 2- to 4-fold lower than the corresponding agar incorporation MIC(90)s, while geometric mean MICs were >5-fold lower. Oritavancin broth macrodilution MIC(90)s were approximately 2- and 5-fold lower than those for metronidazole and vancomycin. Metronidazole was the most active antimicrobial agent against C. difficile using agar incorporation methods. Oritavancin agar incorporation MIC(90)s were unaffected by 0.002% P80 and/or 2% lysed horse blood.
Conclusions:
Oritavancin was at least 4-fold more potent than vancomycin against the majority (25/33) of C. difficile strains tested by broth macrodilution. Oritavancin activity may be underestimated by agar incorporation methods, regardless of the use of P80 or lysed horse blood.
Insights
Oritavancin demonstrates potent activity against Clostridium difficile (C. diff) strains, showing at least 4-fold greater potency than vancomycin via broth macrodilution. Agar incorporation methods may underestimate oritavancin
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Clostridium difficile infection (CDI) is a growing nosocomial concern.
- Current first-line treatments include metronidazole and vancomycin.
- Oritavancin, a lipoglycopeptide, exhibits activity against Gram-positive pathogens.
Purpose of the Study:
- To determine and compare the in vitro activity of oritavancin, metronidazole, and vancomycin against diverse Clostridium difficile strains.
- To evaluate the influence of agar incorporation method supplements on oritavancin's Minimum Inhibitory Concentration (MIC).
Main Methods:
- Genotypic characterization of 33 C. difficile strains using PCR ribotyping.
- Determination of MICs via agar incorporation and broth macrodilution methods.
- Testing oritavancin MICs on agar plates with and without polysorbate-80 and lysed horse blood.
Main Results:
- Broth macrodilution yielded lower MICs for oritavancin compared to agar incorporation.
- Oritavancin MIC(90)s were 2- to 4-fold lower by broth macrodilution than agar incorporation.
- Oritavancin showed 2- to 5-fold greater potency than vancomycin via broth macrodilution.
Conclusions:
- Oritavancin is significantly more potent than vancomycin against most C. difficile strains tested.
- Agar incorporation methods may underestimate the true in vitro activity of oritavancin.
- Oritavancin's efficacy against C. difficile warrants further investigation.
Related Concept Videos
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
Antibiotic Selection
Development of Antibiotic Resistance
